Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban (CASTA-DIVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02746185
Recruitment Status : Completed
First Posted : April 21, 2016
Last Update Posted : August 13, 2018
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous dalteparin in patients with cancer associated thrombosis. It is designed as a non-inferiority open label randomized multicenter trial with blinded adjudication of outcome events.

Condition or disease Intervention/treatment Phase
Neoplasm Venous Thromboembolism Drug: rivaroxaban Drug: Low-molecular-weight heparin Phase 3

Detailed Description:
Patients with active cancer and symptomatic pulmonary embolism, proximal deep vein thrombosis, iliac or caval thrombosis will be randomly assigned to receive either dalteparin using the CLOT regimen or to oral rivaroxaban using the conventional dosage given in the Einstein studies. Experimental and control treatments will be given for three months. The main outcome at three month will include all symptomatic and incidentally discovered venous thromboembolic events including pulmonary embolism (either objectively confirmed and death due to pulmonary embolism), lower limb and upper limb deep vein thrombosis, iliac, caval and visceral thrombosis and any worsening of vascular obstruction which will be collected systematically at inclusion and at day 90. The safety end-points will consist of the rate of major bleedings and the composite of major and non-major but clinically significant bleedings at day 90. All outcome events will be blindly adjudicated by a central independent adjudication committee.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 159 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.
Actual Study Start Date : September 2016
Actual Primary Completion Date : April 25, 2018
Actual Study Completion Date : April 25, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Low-molecular-weight heparin
dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months
Drug: Low-molecular-weight heparin
dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
Other Name: dalteparin

Experimental: Rivaroxaban
rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks
Drug: rivaroxaban
rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
Other Name: xarelto

Primary Outcome Measures :
  1. Symptomatic DVT [ Time Frame: 3 months ]
    Recurrent VTE during the 3-month treatment period including all symptomatic DVT (lower limbs distal and proximal DVTs, iliac and caval thrombosis, visceral thrombosis and deep vein thrombosis of the arm)

  2. Symptomatic PE [ Time Frame: 3 months ]
    Recurrent VTE during the 3-month treatment period including symptomatic PE

  3. Unsuspected PE and DVT [ Time Frame: 3 months ]
    Recurrent VTE during the 3-month treatment period including clinically unsuspected PE and DVT discovered incidentally

  4. Worsening of pulmonary vascular or venous obstruction [ Time Frame: 3 months ]
    Recurrent VTE during the 3-month treatment period including worsening of pulmonary vascular obstruction or venous obstruction on the systematic examinations performed at the end of the 3-month treatment period

Secondary Outcome Measures :
  1. Major and clinically significant bleedings during the 3-month treatment period [ Time Frame: 3 months ]
    Major bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and includes any bleeding resulting in death; symptomatic bleeding in a critical organ including intracranial, intra spinal, intraocular, retroperitoneal, intra articular and pericardial bleeding and muscle bleeding resulting in compartment syndrome; symptomatic bleeding resulting in a decrease in the hemoglobin concentration of at least 2g/dL or resulting in the transfusion of at least two packs of blood red cells.

  2. Symptomatic recurrences of PE or DVT of the legs [ Time Frame: 3 months ]
    excluding visceral thrombosis, upper extremity deep vein thrombosis and clinically unsuspected PE and DVT diagnosed incidentally

  3. Major and non-major clinically significant bleedings at day 90 [ Time Frame: 3 months ]
    Clinically significant non-major bleedings are defined as any bleeding requiring hospitalization or a medical intervention including temporary withholding of anticoagulant treatment to stop bleeding.

  4. Mortality [ Time Frame: 3 months ]

Other Outcome Measures:
  1. Rivaroxaban plasma concentrations [ Time Frame: 3 months ]
    Area under the plasma concentration versus time curve (AUC) determined using a liquid chromatography-tandem mass spectrometry method

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years
  • Social security affiliation
  • Written informed consent
  • Solid active cancer, high grade lymphoma or myeloma treated with Immunomodulatory drugs (IMiDs) (thalidomide or lenalidomide). Active cancer is defined as the presence of measurable disease or ongoing (or planned) chemotherapy, radiotherapy or targeted therapy at inclusion.
  • Histologically or cytologically proven cancer.
  • Symptomatic venous thromboembolism objectively confirmed diagnosed because of symptoms or discovered incidentally
  • High-risk of recurrent Venous thromboembolism (VTE) defined by a score of 0 or ≥ 1, using the following criteria: female sex (+1), lung cancer (+1), breast cancer (-1) non metastatic tumor (-2), previous VTE (+1).

Exclusion Criteria:

  • Exclusive adjuvant hormonal treatment with no measurable residual disease
  • Sub-segmental isolated pulmonary embolism (PE) without associated proximal DVT
  • Isolated distal deep vein thrombosis (DVT) of the legs
  • Isolated upper-extremity DVT or superior vena cava thrombosis
  • Isolated visceral thrombosis
  • Platelet count < 50 000 G/L
  • Active bleeding
  • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C
  • Hemostatic defect with contraindication to anticoagulant treatment at therapeutic dosage
  • Vena cava filter at inclusion
  • Fibrinolytic therapy within 3 days preceding inclusion
  • Creatinine clearance < 30 ml/min according to Cockcroft-Gault formula
  • Previous heparin-induced thrombocytopenia
  • Anticoagulant treatment at curative dosage for more than 3 days before inclusion
  • Pregnancy or lack of effective contraceptive treatment for women of childbearing age
  • Treatment with both strong CYP3A4 and P-glycoprotein (PgP) inhibitors: protease inhibitors for HIV disease, systemic ketoconazole
  • Treatment with a strong CYP3A4 inducer: rifampicin, carbamazepine, phenytoin.
  • Life expectancy < 3 months
  • Eastern Cooperative Oncology Group (ECOG) level 3 or 4

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02746185

Layout table for location information
CHU Amiens - Medecine vasculaire (003)
Amiens, France
CHU Angers - Medecin Interne (002)
Angers, France
Espace Artois Santé
Arras, France
Hopital Saint Andre - Medecine vasculaire (015)
Bordeaux, France
CHU Brest - Departement de medecin interne et pneumologie (008)
Brest, France
CHU Le Bocage - Medecine interne 1 (014)
Dijon, France
CHU Grenoble - Medecine vasculaire (007)
Grenoble, France
CH Départemental La Roche sur Yon
La Roche-sur-Yon, France
Centre hospitalier Lyon Sud - Medecine interne (011)
Lyon, France
CHRU de Nîmes - Pneumologie (012)
Nîmes, France
HEGP - Pneumologie et soins intensifs (001)
Paris, France, 75015
Institut Curie - Soins de support en Cancerologie (020)
Paris, France
CHU Saint Etienne - Medecin vasculaire et therapeutique (006)
Saint Etienne, France
Hopital Saine Musse - Service de Medecine Vasculaire (010)
Toulon, France
CHU Rangueil - Medecin Vasculaire (019)
Toulouse, France
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Layout table for investigator information
Principal Investigator: Guy Meyer, MD APHP - HEGP
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT02746185    
Other Study ID Numbers: P141204
First Posted: April 21, 2016    Key Record Dates
Last Update Posted: August 13, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Assistance Publique - Hôpitaux de Paris:
venous thromboembolism
low-molecular weight heparin
Additional relevant MeSH terms:
Layout table for MeSH terms
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Heparin, Low-Molecular-Weight
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors